Novartis (Novn) Gains Q4, Annual Year Fy24

Swiss pharmaceutical giant Novartis On Friday he reported better than expected sales in the fourth quarter, but not reaching its own orientation during the stretch of the whole year.

Net sales of the fourth quarter increased 16% in a constant currency to $ 13.2 billion, compared to the $ 12,795 billion estimated by analysts in a LSEs survey.

The central operating income adjusted quarterly reached $ 4.86 billion compared to the $ 4.23 billion expected.

By 2024, net sales increased 12% in a constant currency to $ 50,32 billion, versus $ 50.47 billion forecast. The central operational income of the entire year increased 22% to $ 19.5 billion compared to $ 17.02 billion forecast.

Novartis had raised his 2024 earning guide for the third consecutive quarter in October, saying that he hoped that full -year net sales and central operating income will grow in the percentages of “high adolescents” versus the previously previously predicted prognosis of “adolescents media to high “.

CEO Vas Narasimhan said that the results marked a positive early signal since it implemented a strategic business review in 2023.

“In our first full year as an innovative company in innovative medicines, Novartis offered one of the strongest financial yields in our history, increasing sales of 12% CC (constant currencies) and central operating income of 22% of CC,” Narasimhan said In a statement accompanying the results.

“With the impulse we are seeing in the business, we hope to continue with our strong sales growth with margin expansion in 2025 and we continue on the way to fulfill our orientation in the middle of the period,” he said.

Looking towards the future, Narasimhan said that the company focused on advancing its development pipe, including more than 30 assets “with the potential to boost long -term differentiated growth.”

This is a last minute news and will be updated shortly.